INTRODUCTION
Late restenosis with clinical complications after percutaneous coronary interventions (PCI) with stents is becoming a more significant issue [1, 2].
Intravascular alterations in patients with myocardial infarction in the remote period after PCI provided grounds for their classification into a special group of alterations in the stented coronary arteries called neoatherosclerosis [3]. Later restenoses in stents differ from early restenosis caused by fibromuscular proliferation. By structural peculiarities, they have a lot in common with native (natural) atherosclerosis [4]. The study was aimed to compare lipid parameters in the remote period in two groups of patients after PCI: with and without restenosis in stents.
MATERIALS AND METHODS
The analysis included primary and angiographic data and blood lipid parameters of 66 patients with ischemic heart disease that underwent angioplasty and stenting and further repeated coronarography (CAG) for the observed clinical worsening more than 9 months after the primary intervention (median (Me) of the observation period Me 632 [380;904] days).
During the period of observation, patients received pharmacotherapy that included antiplatelet therapy, statins, inhibitors of the angiotensin-converting enzyme, and antianginal therapy. Patients received written recommendations on the factors of cardiovascular risk. Repeated hospitalization and examination were performed by the clinical indications: acute coronary syndrome (ACS), angina or other clinical manifestations that required specific diagnostics in inpatient conditions. Patients underwent CAG and repeated PCI when it was necessary.
The study was approved by the ethical committee and all patients signed the form of informed consent.
Patients were divided into two groups depending on the absence (Group I) and presence (Group II) of restenosis in the stent revealed during the repeated CAG.
Clinical and angiographic parameters, cardiovascular risk in the initial condition (index PCI) and after the repeated observation (“follow-up CAG/PCI”) included age, sex, angina, acute myocardial infarction (MI), ACS, Chronic kidney disease (CKD), arterial hypertension, dyslipidemia, type 2 diabetes mellitus, smoking, physical inactivity, obesity and body mass index (BMI), alcohol abuse, family anamnesis of cardiovascular disease, weight, drug-eluting stent (DES), and bare-metal stent (BMS).
The analysis of blood for lipids was performed in plasma and serum obtained from the venous blood taken 12 hours after the meal. The analyzer Konelab 20i with Human kits was used for the evaluation of the following parameters: cholesterol of high-density lipoproteins (HDL-C), triglycerides (TG), and total cholesterol (TCH). Friedewald formula was used to calculate the cholesterol of low-density lipoproteins (LDL-C). Non-LDL cholesterol was obtained by the difference between TCH and LDL-C.
Statistical analysis.
The obtained data were recorded in Excel tables (Microsoft, USA) and further statistical analysis was performed in SPSS Statistics v23 (IBM, USA). In cases of the normal distribution of the quantitative data, the description was presented as the mean and mean square deviation. The quantitative parameters with high asymmetry were presented as the median (Me), 25th and 75th percentile. Quantitative parameters were described by absolute and relative values and percent. The intergroup comparison was performed with Fisher's test. The difference between quantitative parameters was evaluated with Student's t-test.
RESULTS
“Index-PCI” clinical characteristics and risk factors are presented in Table 1. Angiographic characteristics and stents are described in Table 2. By the baseline data, the groups were comparable by the majority of clinical parameters. A higher rate of unstable angina was observed in the group with developed restenosis (p=0.05), as well as the tendency towards alcohol abuse (p=0.07). Initially, diabetes mellitus was observed more often in the group without restenosis than in the group with restenosis (p=0.06). By the angiographic data, the groups were comparable, except for a higher rate of the application of DES in the group without restenosis (p=0.025).
Table 1
“Index-PCI”. Clinical data in groups with and without stenosis (n=66).
Parameters |
Group 1 (n=34) without restenosis |
Group 2 (n=32) with restenosis
|
p |
|
Age (years) |
62.41±7.94 |
61.94±9.76 |
0.829 |
|
Sex (male) |
21 (61.76%) |
24 (75.00%) |
0.297 |
|
Arterial hypertension |
29 (85.29%) |
30 (93.75%) |
0.428 |
|
Dyslipidemia |
29 (85.29%) |
27 (84.38%) |
0.733 |
|
Obesity |
11 (32.35%) |
9 (28.13%) |
0.792 |
|
Type 2 diabetes mellitus |
10 (29.41%) |
3 (9.38%) |
0.062 |
|
Insulin dependence |
2 (5.88%) |
1 (3.13%) |
1.000 |
|
Clinical worsening in patients with stable ischemic heart disease |
30 (88.24%) |
24 (75.00%) |
0.210 |
|
MI in the anamnesis |
21 (61.76%) |
23 (71.88%) |
0.441 |
|
Acute coronary syndrome, including: |
4 (11.76%) |
8 (25.00%) |
0.210 |
|
acute myocardial infarction |
3 (8.82%) |
3 (9.38%) |
1.000 |
|
unstable angina |
1 (2.94%) |
6 (18.75%) |
0.051 |
|
CKD |
1 (2.94%) |
0 (0.00%) |
1.000 |
|
Smoking Smoked in past |
8 (34.78%) 6 (24.00%) |
5 (20.00%) 4 (19.05%) |
0.690 |
|
Alcohol abuse |
3 (8.82%) |
7 (21.88%) |
0.066 |
|
Familial cardiovascular diseases |
15 (44.12%) |
14 (43.75%) |
1.000 |
|
Physical inactivity |
4 (11.76%) |
3 (9.38%) |
1.000 |
|
Abdominal obesity |
3 (8.82%) |
3 (9.38%) |
1.000 |
|
EF LV, % |
62.33±8.70 |
60.43±6.27 |
0.620 |
|
Weight, kg |
79.00 [72.00;100.00] |
83.50 [78.00;88.00] |
0.735 |
|
BMI (kg/m2) |
27.00 [25.90;30.72] |
27.44 [26.06;30.85] |
0.895 |
|
EF – ejection fraction; LV – left ventricle; median and its 25th and 75th percentile (Me [25;75])
Table 2
“Index-PCI”. Angiographic data in groups with and without restenosis (n=66).
Parameters |
Group 1 (n=34) without restenosis |
Group 2 (n=32) with restenosis |
p |
Variants of blood supply Left Right Balanced |
|
|
0.188 |
4 (11.76%) |
4 (12.50%) |
||
21 (61.76%) |
25 (78.13%) |
||
9 (26.47%) |
3 (9.38%) |
||
Classification of the damage of coronary arteries by the effectiveness of intervention (ACC/AHA) (potential success degree of risk) A (high/low) B (moderate/moderate) C (low/high) |
|
|
0.665 |
12 (35.29%) |
8 (25.00%) |
||
13 (38.24%) |
15 (46.88%) |
||
9 (26.47%) |
9 (28.13%) |
||
Reference arterial diameter in the place of stenting, mm |
3.00 [2.75;3.50] |
3.00 [3.00;3.50] |
0.767 |
Bare Metal Stent (BMS) |
14 (41.18%) |
21 (65.63%) |
0.054 |
Drug-eluting stents (DES) |
18 (52.94%) |
8 (25.00%) |
0.025 |
BMS + DES |
2 (5.88%) |
3 (9.38%) |
0.668 |
PCI in two or more segments |
5 (14.71%) |
12 (37.50%) |
0.049 |
Residual stenosis in the stented vessel, % |
15.00 [0.00;50.00] |
25.00 [5.00;60.00] |
0.419 |
Dissection after PCI |
3 (8.82%) |
0 (0.00%) |
0.239 |
ACC/AHA – American College Of Cardiologists/American Heart Association; median and it 25th and 75th percentile (Me [25;75])
During “follow-up CAG/PCI”, there was no significant difference by the duration of the observation between the groups. Diabetes mellitus significantly prevailed in Group I over Group II. The rate of ACS as the reason for hospitalization was higher in the group with restenosis than in the group without it (Table 3).
In Group II, the degree of restenosis was 80% with the prevalence of the diffuse process. Restenosis was primarily localized in the system of the left coronary artery (Table 4).
The progressing of native atherosclerosis outside the stent was performed in both groups with some prevalence in the group with restenosis (Table 5).
Table 3
“Follow-up CAG/PCI”. Clinical data in groups with and without stenosis (n=66)
Parameters |
Group 1 (n=34) without restenosis |
Group 2 (n=32) with restenosis
|
p |
Age (years) of “follow-up” |
63.41±8.32 |
65.13±9.12 |
0.428 |
Period of “follow-up”, days |
619.50 [418.00;892.00] |
655.00 [349.00;928.50] |
0.865 |
Arterial hypertension |
32 (94.12%) |
29 (90.63%) |
0.668 |
Dislipidemia |
26 (76.47%) |
29 (90.63%) |
1.000 |
Type 2 diabetes mellitus |
13 (38.24%) |
4 (12.50%) |
0.024 |
Insulin-dependence |
2 (5.88%) |
1 (3.13%) |
1.000 |
Clinical worsening in patients with stable ischemic heart disease |
22 (64.71%) |
24 (75.00%) |
0.428 |
MI in the anamnesis |
1 (2.94%) |
2 (6.25%) |
0.608 |
Acute coronary syndrome, including: |
33 (97.06%) |
23 (71.88%) |
0.005 |
acute myocardial infarction |
1 (2.94%) |
9 (28.13%) |
0.005 |
unstable angina |
0 (0.00%) |
3 (9.38%) |
0.108 |
CKD |
1 (2.94%) |
6 (18.75%) |
0.051 |
Insulin-dependence |
3 (8.82%) |
3 (9.38%) |
1.000 |
median and its 25th and 75th percentile (Me [25;75])
Table 4
“Follow-up CAG/PCI”. Angiographic characteristics of restenosis (n=32)
Parameters |
Group II with restenosis |
Degree of restenosis in the place of stent grafting, % |
80 [75;99] |
Type of restenosis Local Diffuse |
|
11 (34.38%) |
|
19 (59.38%) |
|
Multifocal |
2 (6.25%) |
Arteria with restenosis Anterior interventricular branch Circumflex branch Right coronary artery |
|
13 (40.63%) |
|
13 (40.63%) |
|
6 (18.75%) |
median and its 25th and 75th percentile (Me [25;75])
Table 5
“Follow-up CAG/PCI”. Angiographic data in the group of patients with and without restenosis (n=66)
Parameters |
Group 1 (n=34) without restenosis |
Group 2 (n=32) with restenosis
|
p |
Progressing of native coronary atherosclerosis
|
13 (38.24%) |
18 (56.25%) |
0.167 |
Intracoronary blood clot |
1 (2.94%) |
3 (9.38%) |
1.000 |
The rate of repeated PCI during “follow-up” was significantly higher in the group with restenosis than in the group without restenosis (71% and 97%, respectively, p=0.006).
By the parameters of the lipid spectrum, there was no significant difference between Groups I and II in “index-PCI”. The level of glucose was higher in Group I than Group II (Me 5.8 [5.1;6.8] and Me 5.3 [5.0;5.9], respectively, p=0.053) (Table 6).
During the observation (“index PCI” – “follow-up CAG/PCI”), the mean parameters in groups decreased in the level of TCH, LDL-C, Very Low-Density Lipoprotein Cholesterol (VLDL-C), HDL-C, and TG.
The intergroup comparison of “follow-up CAG/PCI” showed that the level of TCH was higher in Group I (Me 4.7 [4.3;5.7]) than in Group II (Me 4.5 [3.9;5.0]) (p=0.051), the level of non-HDL-C was significantly higher in Group I than in Group II (Me 3.6 [3.1;4.7] and Me 3.3 [2.8;3.8], respectively, p=0.033). By the parameters HDL-C, TG, creatinine, and glucose, the parameters of the groups were comparable.
Table 6
Dynamic parameters of lipid spectrum and main biochemical markers in groups of patients with and without restenosis during “index-PCI” and “follow-up CAG/PCI”.
|
Group I without restenosis index (n=34) |
Group II with restenosis index (n=32) |
p index |
Group 1 without restenosis follow-up (n=34) |
Group II with restenosis follow-up (n=32) |
p follow-up |
Delta group 1 without restenosis |
Delta group 2 with restenosis |
TCH, |
5.30 |
5.10 |
0.210 |
4.70 |
4.50 |
0.051 |
-0.60 (- |
-0.60 (- |
mmol/L |
[4.60;6.80] |
[3.75;6.30] |
[4.25;5.65] |
[3.90;5.00] |
11.32%) |
12.24%) |
||
LDL-C, |
2.96 |
3.08 |
0.659 |
2.84 |
2.58 |
0.082 |
-0.12 (- |
-0.39 (- |
mmol/L |
[2.46;4.14] |
[2.21;3.83] |
[2.47;4.05] |
[2.09;3.11] |
3.59%) |
12.70%) |
||
VLDL-C, |
0.70 |
0.68 |
0.970 |
0.68 |
0.67 |
0.817 |
-0.02 (- |
-0.01 (- |
mmol/L |
[0.49;0.90] |
[0.56;1.11] |
[0.50;0.90] |
[0.50;0.88] |
2.13%) |
1.28%) |
||
HDL-C, |
1.20 |
1.07 |
0.240 |
1.08 |
1.19 |
0.645 |
-0.12 (- |
0.12 |
mmol/L |
[0.97;1.39] |
[0.87;1.37] |
|
[0.88;1.26] |
[0.88;1.26] |
|
12.12%) |
(12.12%) |
Non-HDL-C, Mmol/L |
4.00 [3.16;5.39] |
3.82 [2.59;5.09] |
0.121 |
3.57 [3.09;4.71] |
3.32 [2.78;3.80] |
0.033 |
-0.43 (- 9.93%) |
-0.50 (- 12.85%) |
TG, mmol/L |
1.57 [1.07;2.37] |
1.55 [1.21;2.42] |
0.476 |
1.48 [1.09;1.98] |
1.44 [0.97;2.04] |
0.775 |
-0.09 (- 4.52%) |
-0.11 (- 6.51%) |
|
99.00 |
94.50 |
|
|
|
|
|
|
Creatinine, |
[84.00;107.0 |
[84.50;101.5 |
0.985 |
94.00 |
90.50 |
0.377 |
-5.00 (- |
-4.00 (- |
µmol/L |
0] |
0] |
|
[85.00;102.00] |
[78.00;109.00] |
|
4.92%) |
4.17%) |
median and its 25th and 75th percentile (Me [25;75])
A higher level of LDL-C was observed in Group I in comparison with Group II (Me 2.8 [2.5;4.1] and Me 2.6 [2.1;3.1], respectively, p=0.082).
The detailed distribution of the parameters LDL-C depending on the recommended target values is presented in Table 7. LDL-C lower than 1.8 mmol/L was observed more often in patients with clinical worsening in a remote period (groups with late complications in patients with and without stenosis: 13.9% and 15%, respectively) than in the early period (Groups I and II: 4.4% and 4.0%, respectively). There were no differences between the groups with and without restenosis in the stent in patients with the level of LDL-C lower than 1.8 mmol/L. The parameter values lower than 1.5 mmol/L were quite rare. In all the groups, regardless of the period of observation and the presence of stenosis in the stent, the parameter values higher than 2.6 mmol/L prevailed.
Table 7
Target levels of lipid parameters at the stage of “follow-up CAG/PCI”
Parameters |
Late complication without restenosis (n=34) |
Late complications with restenosis (n=32) |
p |
TCH <4 mmol/L |
5 (14.71%) |
8 (25.00%) |
0.540 |
non-HDL-C <2.59 mmol/L |
3 (8.82%) |
6 (18.75%) |
0.477 |
LDL-C <1.8 mmol/L or a 50% decrease from baseline values 1.8–3.5 mmol/L |
1 (2.94%) |
2 (6.25%) |
1.000 |
TG <1.7 mmol/L |
17 (50.00%) |
21 (65.63%) |
0.582 |
During the past years, in the publications, the term “neoatherosclerosis” is defined as a development of restenosis after the stenting of coronary arteries that is similar to traditional atherosclerosis by such serious clinical complications as an acute coronary syndrome and, in some cases, thrombosis of coronary arteries [3]. Visual pictures obtained during intracoronary ultrasound imaging, especially, during optic coherent tomography, and accumulated morphological data allow the specialists to differentiate fibromuscular proliferation, typical for early restenosis, and neoatherosclerosis [5]. Neoatherosclerosis is characterized by the formation of lipid plaques with the elements of capsule damage and thrombosing. The pathogenesis of atherosclerosis includes the most important element – lipid alterations, which are confirmed by a prognostic significance of cholesterol metabolism and the expected effectiveness of hypolipidemic therapy, including statins [6]. This factor can also affect the formation of neoatherosclerosis in the stent that develops at the later stages after PCI.
In the present study, patients were treated as a group of very high and extreme risk by the clinical characteristics and damage of coronary arteries. In the initial phase of “index PCI”, the majority of patients had high and moderate levels of LDL-C and there were no differences by these parameters between the groups. During the remote repeated examination, lipid characteristics improved in the groups with and without restenosis, including a decrease in LDL-C, which was insufficient for the target levels despite strict dietary recommendations and statin therapy. At the final stage of “follow-up”, the lack of a significant difference by the lipid parameters between the groups with and without restenosis in the stents did not provide grounds for the casual role of lipids in the development of neoatherosclerosis in patients with late restenosis.
There are also other factors of atherosclerotic progressing in the development of restenosis [7]. The influence of an increased level of genetically determined lipoprotein was observed [8] and the involvement of inflammatory and immune factors, the significance of which was confirmed by the effectiveness of anti-inflammatory therapy [9]. New factors were revealed that influenced the accelerated development of atherosclerosis in the drug-eluting stents, in particular, perilipin 2 [10].
CONCLUSIONS
In the remote period after PCI, the level of lipids in blood did not reach the target level and their values were worse in the group without restenosis than with restenosis. The development of natural atherosclerosis remains the dominating factor of clinical worsening at the remote period after the stenting of coronary arteries.
FINANCIAL SUPPORT AND SPONSORSHIP
Nil.
CONFLICTS OF INTEREST
The authors declare no conflict of interest